Cardiovascular safety of triptans

Cephalalgia

Volumn 24, Issue 7, 2004, Pages 513-514

  Dodick, D W ^a   Papademetriou, V ^b  

^a MAYO CLINIC   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMIGRAINE AGENT; ELETRIPTAN; SEROTONIN AGONIST; SUMATRIPTAN; TRIPTAN DERIVATIVE; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CARDIOVASCULAR SYMPTOM; CLINICAL TRIAL; CORONARY ARTERY; CORONARY ARTERY CONSTRICTION; CORONARY ARTERY DISEASE; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; EDITORIAL; HIGH RISK PATIENT; HUMAN; MAXIMUM ALLOWABLE CONCENTRATION; MIGRAINE; THORAX PAIN; VASOSPASM;

CARDIOVASCULAR DISEASES; HUMANS; INDOLES; PYRROLIDINES; SUMATRIPTAN; TRYPTAMINES;

EID: 4644228660     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-2982.2003.00714.x     Document Type: Editorial

References (16)

1. MacGregor EA, Brandes J, Eikermann A. Migraine prevalence and treatment patterns: the global Migraine and Zolmitriptan Evaluation survey. Headache 2003; 43:19-26.
2. Matchar DB, Young WB, Rosenberg JH. Multispecialty consensus on diagnosis and treatment of headache: pharmacological management of acute attacks. Neurology 2000; 54: http://www.aan.com/public/practiceguide lines/03.pdf Accessed 16 February 2002.
3. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001; 41:646-57.
4. Young WB, Mannix L, Adelman JU, Shechter AL. Cardiac risk factors and the use of triptans: a survey study. Headache 2000; 40:587-91.
5. Dodick DW, Lipton RB, Martin VT, Papademetriou V, Rasamond W, Maassen van Derdrink et al. The Triptan Cardiovascular Safety Expert Panel. Consensus statement: Cardiovascular safety of Triptans (5HT1B/1D agonists) in the acute treatment of migraine. Arch Int Med in press.
6. Houghton LA, Foster J, Whorwell PJ, Morris J, Fowler P. Is chest pain after sumatriptan oesophageal in origin? Lancet 1994; 344:985-6.
7. Boska MD, Welch KM, Schultz L, Nelson J. Effects of the anti-migraine drug sumatriptan on muscle energy metabolism: relationship to side-effects. Cephalalgia 2000; 20:39-44.
8. MacLean MR, Clayton RA, Templeton AG, Morecroft I. Evidence for 5-HT-1-like receptor-mediated vasoconstriction in human pulmonary artery. Br J Pharmacol 1996; 119:277-82.
9. Sarkar S, Aziz Q, Woolf CJ, Hobson AR, Thompson DG. Contribution of central sensitization to the development of non-cardiac chest pain. Lancet 2000; 356:1154-9.
10. Goldstein JA, Massey KD, Kirby S, Gibson M, Hettiarachchi J, Rankin AJ, Jackson NC. Effect of high-dose intravenous eletriptan on coronary artery diameter. Cephalalgia 2004; 24:515-21.
11. 1 receptor agonist, on central haemodynamics and the coronary circulation. Br J Clin Pharmacol 1992; 34:541-6.
12. 1 agonist, on the systemic, pulmonary, and coronary circulation. Circulation 1993; 87:401-5.
13. Hood S, Birnie D, Swan L, Murray LS, Whitehouse H, Winter P et al. Effects of subcutaneous naratriptan on systemic and pulmonary haemodynamics and coronary artery diameter in humans. J Cardiovasc Pharmacol 1999; 34:89-94.
14. 1B/1D receptor agonist. Clin Pharmacol Ther 1999; 66:85-90.
15. Evers S, Husstedt I-W, Enbergs A. Coronary angiography in migraine patient after subcutaneous sumatriptan. Lancet 1995; 345:198.
16. 3 positron emission tomography. Neurology 1997; 48:1542-50.